Suk-Joon Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2661770/publications.pdf

Version: 2024-02-01

93 papers 2,348 citations

304602 22 h-index 233338 45 g-index

98 all docs 98 docs citations 98 times ranked 2947 citing authors

#	Article	IF	Citations
1	Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecologic Oncology, 2013, 130, 493-498.	0.6	338
2	Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer. Annals of Surgical Oncology, 2012, 19, 4059-4067.	0.7	166
3	Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining â€~optimal' residual disease. Gynecologic Oncology, 2012, 125, 483-492.	0.6	152
4	Clinical characteristics of struma ovarii. Journal of Gynecologic Oncology, 2008, 19, 135.	1.0	139
5	Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical hysterectomy in patients with early cervical cancer. Journal of Obstetrics and Gynaecology Research, 2016, 42, 77-86.	0.6	125
6	Role of aggressive surgical cytoreduction in advanced ovarian cancer. Journal of Gynecologic Oncology, 2015, 26, 336.	1.0	110
7	Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer Journal of Clinical Oncology, 2017, 35, 5520-5520.	0.8	75
8	Longâ€ŧerm outcomes after fertilityâ€sparing laparoscopic radical trachelectomy in young women with earlyâ€stage cervical cancer: An Asan Gynecologic Cancer Group (AGCG) study. Journal of Surgical Oncology, 2014, 110, 252-257.	0.8	70
9	Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 476-481.	1.3	49
10	Lymphatic Embolization for the Treatment of Pelvic Lymphoceles: Preliminary Experience in Five Patients. Journal of Vascular and Interventional Radiology, 2016, 27, 1170-1176.	0.2	49
11	Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecologic Oncology, 2012, 126, 381-386.	0.6	48
12	Comparison of Laparoscopic Versus Abdominal Radical Hysterectomy for FIGO Stage IB and IIA Cervical Cancer With Tumor Diameter of 3 cm or Greater. International Journal of Gynecological Cancer, 2014, 24, 280-288.	1.2	46
13	A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer. Gynecologic Oncology, 2012, 126, 82-86.	0.6	45
14	Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer. Anticancer Research, 2016, 36, 3541-7.	0.5	40
15	Robotic single-site versus laparoendoscopic single-site hysterectomy: a propensity score matching study. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 1043-1050.	1.3	34
16	Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy. Gynecologic Oncology, 2016, 142, 109-114.	0.6	27
17	Lymphatic Leak Occurring After Surgical Lymph Node Dissection: A Preliminary Study Assessing the Feasibility and Outcome of Lymphatic Embolization. CardioVascular and Interventional Radiology, 2016, 39, 1728-1735.	0.9	27
18	Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix. Gynecologic Oncology, 2014, 135, 468-473.	0.6	25

#	Article	IF	CITATIONS
19	Paraâ€aortic lymphadenectomy improves survival in patients with intermediate to highâ€risk endometrial carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1361-1369.	1.3	24
20	Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. Journal of Gynecologic Oncology, 2013, 24, 186.	1.0	24
21	Para-aortic Lymphadenectomy in the Management of Preoperative Grade 1 Endometrial Cancer Confined to the Uterine Corpus. Annals of Surgical Oncology, 2010, 17, 3234-3240.	0.7	23
22	Comparison of laparoscopic versus conventional open surgical staging procedure for endometrial cancer. Journal of Gynecologic Oncology, 2010, 21, 106.	1.0	23
23	Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria. Journal of Gynecologic Oncology, 2015, 26, 32.	1.0	23
24	Surgical management of recurrent ovarian cancer. Gynecologic Oncology, 2016, 142, 357-367.	0.6	23
25	Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis. Gynecologic Oncology, 2016, 141, 440-446.	0.6	23
26	Surgical technique of <i>en bloc</i> pelvic resection for advanced ovarian cancer. Journal of Gynecologic Oncology, 2015, 26, 155.	1.0	22
27	Learning curve analysis of laparoscopic radical hysterectomy for gynecologic oncologists without open counterpart experience. Obstetrics and Gynecology Science, 2015, 58, 377.	0.6	22
28	Lymph-Vascular Space Invasion as a Significant Risk Factor for Isolated Para-aortic Lymph Node Metastasis in Endometrial Cancer: A Study of 203 Consecutive Patients. Annals of Surgical Oncology, 2011, 18, 58-64.	0.7	21
29	Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. Journal of Gynecologic Oncology, 2013, 24, 29.	1.0	21
30	Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. Journal of Gynecologic Oncology, 2018, 29, e56.	1.0	20
31	Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. Journal of Gynecologic Oncology, 2012, 23, 235.	1.0	19
32	Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: A multivariate analysis of 506 cases. Gynecologic Oncology, 2015, 138, 89-93.	0.6	18
33	Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?. Journal of Gynecologic Oncology, 2008, 19, 113.	1.0	17
34	Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study. Annals of Surgical Oncology, 2012, 19, 1973-1979.	0.7	17
35	Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). Journal of Gynecologic Oncology, 2022, 33, .	1.0	17
36	Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 126-130.	1.3	16

#	Article	IF	Citations
37	Treatment Patterns and Outcomes in Bulky Stage IB2 Cervical Cancer Patients: A Single Institution's Experience over 14 Years. Gynecologic and Obstetric Investigation, 2011, 71, 19-23.	0.7	16
38	Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases. Journal of Gynecologic Oncology, 2013, 24, 229.	1.0	16
39	Prediction of lymph node metastasis in patients with apparent early endometrial cancer. Obstetrics and Gynecology Science, 2015, 58, 385.	0.6	16
40	Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer. Strahlentherapie Und Onkologie, 2017, 193, 534-542.	1.0	16
41	Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. Journal of Gynecologic Oncology, 2008, 19, 169.	1.0	15
42	Umbilical Artery Doppler Study as a Predictive Marker of Perinatal Outcome in Preterm Small for Gestational Age Infants. Yonsei Medical Journal, 2009, 50, 39.	0.9	15
43	Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO). Journal of Gynecologic Oncology, 2016, 27, e36.	1.0	15
44	Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer. Journal of Surgical Oncology, 2019, 119, 1011-1015.	0.8	14
45	Surgical manual of the Korean Gynecologic Oncology Group: classification of hysterectomy and lymphadenectomy. Journal of Gynecologic Oncology, 2017, 28, e5.	1.0	13
46	Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy. Obstetrics and Gynecology Science, 2014, 57, 539.	0.6	12
47	Treatment outcomes in patients with FIGO stage IB–IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study. Gynecologic Oncology, 2016, 143, 77-82.	0.6	12
48	Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma. Obstetrics and Gynecology Science, 2019, 62, 27.	0.6	12
49	Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization. Journal of Gynecologic Oncology, 2016, 27, e44.	1.0	11
50	A Predictive Model for Parametrial Invasion in Patients With FIGO Stage IB Cervical Cancer: Individualized Approach for Primary Treatment. International Journal of Gynecological Cancer, 2016, 26, 184-191.	1.2	11
51	Clinical characteristics and prognostic inflection points among longâ€term survivors of advanced epithelial ovarian cancer. International Journal of Gynecology and Obstetrics, 2017, 139, 352-357.	1.0	11
52	Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer. Journal of Gynecologic Oncology, 2020, 31, e7.	1.0	11
53	Practice Patterns of Hereditary Ovarian Cancer Management in Korea. International Journal of Gynecological Cancer, 2017, 27, 895-899.	1.2	10
54	Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision. Gynecologic Oncology, 2019, 153, 362-367.	0.6	10

#	Article	IF	Citations
55	Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis. Gynecologic Oncology, 2016, 143, 688-689.	0.6	9
56	Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. Tumor Biology, 2017, 39, 101042831773314.	0.8	9
57	Conservative management of stage IA1 squamous cell carcinoma of the cervix with positive resection margins after conization. International Journal of Gynecology and Obstetrics, 2010, 109, 110-112.	1.0	8
58	Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study. Journal of Gynecologic Oncology, 2019, 30, e44.	1.0	8
59	The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma. Journal of Gynecologic Oncology, 2010, 21, 50.	1.0	7
60	Pelvic Castleman's disease presenting as an adnexal tumor in a young woman. Obstetrics and Gynecology Science, 2015, 58, 323.	0.6	7
61	Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer. Tumor Biology, 2017, 39, 101042831769430.	0.8	7
62	A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2018, 44, 1294-1301.	0.6	7
63	Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy warrants trial treatment modification. Journal of Gynecologic Oncology, 2009, 20, 17.	1.0	6
64	Value of Sonohysterography in Preoperative Assessment of Myometrial Invasion for Patients With Endometrial Cancer. Journal of Ultrasound in Medicine, 2010, 29, 923-929.	0.8	6
65	Transvaginal Sonography-Guided Core Biopsy of Adnexal Masses as a Useful Diagnostic Alternative Replacing Cytologic Examination or Laparoscopy in Advanced Ovarian Cancer Patients. International Journal of Gynecological Cancer, 2016, 26, 1041-1047.	1.2	6
66	Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery. Gynecologic Oncology, 2018, 151, 32-38.	0.6	6
67	Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline. Journal of Gynecologic Oncology, 2019, 30, e31.	1.0	6
68	Solution to prevent tumor spillage in minimally invasive radical hysterectomy using the endoscopic stapler for treating early-stage cervical cancer: Surgical technique with video. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102211.	0.6	6
69	Reliability of magnetic resonance imaging for bladder or rectum invasion in cervical cancer. Journal of reproductive medicine, The, 2011, 56, 485-90.	0.2	6
70	Uterine artery-preserving laparoscopic radical trachelectomy for early cervical cancer: Technical aspects. Gynecologic Oncology, 2012, 126, 277-278.	0.6	5
71	Extrapelvic bowel resection and anastomosis in cytoreductive surgery for ovarian cancer. Gland Surgery, 2021, 10, 1207-1211.	0.5	5
72	Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. Journal of Gynecologic Oncology, 2020, 31, e15.	1.0	5

#	Article	IF	CITATIONS
73	Sarcomatoid squamous cell carcinoma of the uterine cervix successfully treated by laparoscopic radical hysterectomy: a case report. Journal of reproductive medicine, The, 2010, 55, 445-8.	0.2	5
74	Laparoscopic para-aortic lymphadenectomy in endometrial cancer patient with left-sided inferior vena cava. Gynecologic Oncology, 2012, 126, 147-148.	0.6	4
75	Role of Hormone Therapy After Primary Surgery for Endometrioma. Reproductive Sciences, 2016, 23, 1011-1018.	1.1	4
76	Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery. Journal of Gynecologic Oncology, 2009, 20, 181.	1.0	3
77	Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers. Journal of Gynecologic Oncology, 2017, 28, e6.	1.0	3
78	Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?. Journal of Gynecologic Oncology, 2021, 32, e51.	1.0	3
79	Comprehensive Staging Surgery Including Complete Pelvic and Para-Aortic Lymphadenectomy Followed by Adjuvant Vaginal Brachytherapy Improves Survival Rates for Intermediate-Risk Endometrial Cancer Patients. Gynecologic and Obstetric Investigation, 2012, 74, 68-75.	0.7	2
80	Surgical management of ovarian cancer. Journal of the Korean Medical Association, 2016, 59, 167.	0.1	2
81	Prognostic factors influencing pelvic, extra-pelvic, and intraperitoneal recurrences in lymph node-negative early-stage cervical cancer patients following radical hysterectomy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 94-99.	0.5	2
82	Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model. Journal of Gynecologic Oncology, 2022, 33, .	1.0	2
83	Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology, 2017, 146, 672-673.	0.6	1
84	Cholecystectomy, porta hepatis stripping, and omental bursectomy. Gland Surgery, 2021, 10, 1230-1234.	0.5	1
85	Treatment outcomes and complications in FIGO stage IIIC and IVB endometrioid endometrial cancer patients presenting as nodal spreads following systematic lymphadenectomy and adjuvant therapy. Journal of Obstetrics and Gynaecology Research, 2021, 47, 3322-3330.	0.6	1
86	Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer. Anticancer Research, 2017, 37, 327-334.	0.5	1
87	In reply. Journal of Gynecologic Oncology, 2008, 19, 280.	1.0	0
88	In reply. Journal of Gynecologic Oncology, 2009, 20, 133.	1.0	0
89	Secondary cytoreductive surgery for recurrent ovarian cancer: who will get the most benefit?. Gynecologic Oncology, 2021, 162, S7.	0.6	0
90	Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma in Korea: three case reports. Yeungnam University Journal of Medicine, 2021, 38, 350-355.	0.7	0

Suk-Joon Chang

#	Article	IF	CITATIONS
91	Reply to A Macrì. Journal of Gynecologic Oncology, 2015, 26, 242.	1.0	0
92	The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study. Anticancer Research, 2022, 42, 363-371.	0.5	0
93	Gynecologic cancer clinical practice guidelines in Korea and current issues. Korean Journal of Women Health Nursing, 0, , .	0.2	0